Current status of cholera and rise of novel mucosal vaccine

Japanese Journal of Infectious Diseases

Volumn 53, Issue 5, 2000, Pages 181-188

  Yamamoto, T ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; BACTERIAL ANTIGEN; BACTERIAL DNA; BACTERIAL TOXIN; BACTERIUM ANTIBODY; BILIRUBIN; BIOLOGICAL MARKER; CALCITRIOL; CHLORIDE ION; CHOLERA TOXIN; CHOLERA VACCINE; COBALT 60; CYCLIC AMP; DIPHTHERIA VACCINE; ENTEROTOXIN; FORMALDEHYDE; HEMOLYSIN; HYDROCHLORIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIVE VACCINE; MONOCLONAL ANTIBODY; OLIGOSACCHARIDE; PLASMID DNA; POTASSIUM ION; PROTEIN SUBUNIT; SECRETORY IMMUNOGLOBULIN; SODIUM ION; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BACTERIUM MUTANT; BETA CHAIN; CHEMOPROPHYLAXIS; CHILD; CHOLERA; COBALT THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; ENDEMIC DISEASE; EPIDEMIC; EPIDEMIOLOGICAL DATA; ESCHERICHIA COLI; HEAT TREATMENT; HUMAN; IMMUNITY; INTESTINE MUCOSA; IRRADIATION; MOUSE; NONHUMAN; REVIEW; SEROTYPE; TRAVEL; VACCINATION;

CHILD, PRESCHOOL; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; HUMANS; IMMUNITY, MUCOSAL; VIBRIO CHOLERAE;

EID: 0034480794     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Cholera during last hundred years (1884-1983)
2. Serotype conversion in Vibrio cholerae 01
3. Lipopolysaccharides of Escherichia coli K12 strains that express cloned genes for the Ogawa and Inaba antigens of Vibrio cholerae 01: Identification of O-antigenic factors
4. Pathogenesis of experimental cholera: Preparation and isolation of choleragen and choleragenoid
5. Lysogenic conversion by a filamentous phage encoding cholera toxin
6. A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria
7. DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae
8. From the cover: Climate and infectious disease: Use of remote sensing for detection of Vibrio cholerae by indirect measurement
9. Live oral vaccines against cholera: An update
10. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori
11. Vibrio cholerae adherence and colonization in experimental cholera: Electron microscopic studies
12. Electron microscopic study of Vibrio cholerae O1 adherence to the mucus coat and villus surface in the human small intestine
13. Impact of infection by Helicobacter pylori on the risk and severity of endemic cholera
14. ABO blood groups and cholera
15. Pathophysiology and treatment of cholera
16. Pathophysiology and clinical aspect
17. Cholera: Pathophysiology, clinical features, and treatment
18. Vibrio cholerae
19. Cholera in the Americas
20. Cholera in 1991
21. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India
22. Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh
23. Cholera in 1993
24. Vibrio cholerae non-O1 - The eighth pandemic?
25. Cholera in 1994
26. Oral vaccines against cholera: Lessons from Vietnam and elsewhere
27. Cholerae in Japan, 1975-1997
28. Cholera, 1999
29. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 E1 Tor after vaccination
30. Cholera in 1994
31. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area
32. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children
33. Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR
34. Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama
35. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1
36. Vibrio cholerae O139 conjugate vaccines: Synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice
37. Field trial of oral cholera vaccines in Bangladesh
38. Field trial of oral cholera vaccines in Bangladesh: Results from three-year follow-up
39. Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers
40. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia
41. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits
42. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru
43. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam
44. The complement system in host defense and inflammation
45. The mucosal immune system: From fundamental concepts to vaccine development
46. The induction of systemic and mucosal immune responses following the subcutaneous immunization of mature adult mice: Characterization of the anti-bodies in mucosal secretions of animals immunized with antigen a vitamin D3 adjuvant
47. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
48. IgG surfaces as an important component in mucosal protection
49. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR
50. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: Results of a large-scale field trial
51. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
52. Molecular basis of vaccination
53. Role of macrophage cytokines in mucosal adjuvanticity
54. The role of Th1 and Th2 cells for mucosal IgA responses
55. Skin immunization made possible by cholera toxin
56. Enterotoxin adjuvants have direct effects on T cells and antigen-presenting cells that result in either interleukin-4-dependent or -independent immune responses
57. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
58. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
59. An oral B subunit: Whole cell vaccine against cholera